Alpha Thalassemia Market By Type (Silent Carrier State, Alpha Thalassemia Trait, Hemoglobin H Disease, And Hydrops Fetalis), By Treatment (Blood Transfusions, Iron Chelation Therapy, Bone Marrow Transplant, And Gene Therapy) By End Users (Hospitals, Clinics, Blood Banks, And Research Institutes), and Region – Global Market Dynamics, Trends, and Opportunities 2023-2032

Number of pages: 200+  |  Report Format: PDF  |  Published date: September, 2023
Historical Years – 2017-2021  |  Base Year – 2022  |  Forecasted Years – 2023 to 2032

A new report titled “Alpha Thalassemia Market – Forecast to 2032” by Eternal Market, the global Alpha Thalassemia industry is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2023 to 2032, reaching a value of USD 6.8 billion by the end of the forecast period.

Global Alpha Thalassemia industry Outlook

Alpha thalassemia is a genetic disorder that affects the production of hemoglobin, a protein found in red blood cells that carries oxygen throughout the body. In alpha thalassemia, the body has reduced or absent production of alpha globin chains, which are essential components of hemoglobin. This leads to a decrease in the number of red blood cells and anemia, which can cause symptoms such as fatigue, weakness, and pale skin. The severity of the disorder can vary, from a mild form known as alpha thalassemia trait, which often has no symptoms, to a severe form known as hemoglobin H disease or alpha thalassemia major, which can be life-threatening.

Growing awareness and screening programs has proliferated the demand for alpha thalassemia.

Awareness programs aimed at educating the public and healthcare professionals about the disorder and its prevalence are leading to increased detection and diagnosis of the condition. Early detection is crucial for effective management and treatment of the condition, and screening programs are being implemented in many countries with high rates of alpha thalassemia to identify carriers and those at risk of developing the disorder.

Moreover, advances in screening technologies, such as prenatal diagnosis and carrier testing, have made it easier and more accessible to identify carriers and those at risk of having children with the disorder. This has led to increased demand for genetic counseling services and prenatal testing for alpha thalassemia.

Advances in diagnosis and treatment has increased the demand for alpha thalassemia.

Advances in diagnosis and treatment of alpha thalassemia are also significant drivers of the market. Diagnosis of alpha thalassemia is typically done through blood tests to measure hemoglobin levels and genetic testing to confirm the presence of the condition. However, recent advancements in diagnostic methods, such as next-generation sequencing and DNA microarrays, have made it easier to detect the condition accurately, leading to better patient outcomes.

In terms of treatment, there have been significant advances in recent years. While the only cure for alpha thalassemia remains hematopoietic stem cell transplantation, there are several treatments available that can improve patients’ quality of life. These include regular blood transfusions to manage anemia, iron chelation therapy to prevent iron overload, and folic acid supplements to support red blood cell production.

The global alpha thalassemia market is segmented based on Type (Silent Carrier State, Alpha Thalassemia Trait, Hemoglobin H Disease, And Hydrops Fetalis), By Treatment (Blood Transfusions, Iron Chelation Therapy, Bone Marrow Transplant, And Gene Therapy) By End Users (Hospitals, Clinics, Blood Banks, And Research Institutes)

Based on type, the silent carrier state, segment is expected to grow at the high rate during the forecast period. In 2022, the segment contributed around 35% of the overall market. The silent carrier state is the most common type of alpha thalassemia. It occurs when a person inherits one abnormal alpha-globin gene from one parent and a normal alpha-globin gene from the other parent. People with the silent carrier state usually do not have any symptoms and are unaware that they carry the abnormal gene. However, they can pass the gene to their children, which may result in alpha thalassemia trait or other forms of alpha thalassemia.

Based on treatment, in 2022, the blood transfusions segment is expected to hold large share of 34% in the market. Blood transfusions can help replace the missing or abnormal hemoglobin and improve the symptoms of anemia. Iron chelation therapy is used to remove excess iron from the body, which can accumulate from frequent blood transfusions.

Based on end user, the hospitals segment is expected to grow with the CAGR of 11.4% during the forecast period. Hospitals are the primary end-users of treatments related to alpha thalassemia. This is because alpha thalassemia is a serious genetic disorder that requires specialized medical care and treatment. Patients with alpha thalassemia may require frequent blood transfusions, iron chelation therapy, and other supportive care, which is often provided in a hospital setting.

Key players operating in the global alpha thalassemia market include Bluebird Bio, Acceleron Pharma, Novartis AG, Sangamo Therapeutics, CRISPR Therapeutics, Global Blood Therapeutics, Celgene Corporation, Shire Pharmaceuticals, ApoPharma Inc., and La Jolla Pharmaceutical Company.

Recent Developments:

In November 2019: FDA approval of Reblozyl (luspatercept-aamt) by Bristol-Myers Squibb and Acceleron Pharma for treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions.

Major Strategies adopted by key market players

  • Agreements, Collaborations, and Partnerships: 34%
  • Acquisitions: _%
  • New Product Launch: _%
  • Other Developments: _%

Scope of the Report:

Global Alpha Thalassemia Market, By Type

  • Silent carrier state
  • Alpha thalassemia trait
  • Hemoglobin h disease
  • Hydrops fetalis

Global Alpha Thalassemia Market, By Treatment

  • Blood transfusions
  • Iron chelation therapy
  • Bone marrow transplant
  • Gene therapy

Global Alpha Thalassemia Market, by End User

  • Hospitals
  • Clinics
  • Blood banks
  • Research institutes

Global Alpha Thalassemia Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of MEA

Companies Profiled

  • Bluebird Bio
  • Acceleron Pharma
  • Novartis AG
  • Sangamo Therapeutics
  • CRISPR Therapeutics
  • Global Blood Therapeutics
  • Celgene Corporation
  • Shire Pharmaceuticals
  • ApoPharma Inc.
  • La Jolla Pharmaceutical Company
  • Other Companies

*The report scope shall be customized as per the requirements

Chapter 1 Global Alpha Thalassemia Market Overview
1.1 Introduction
1.2 Drivers for Alpha Thalassemia Market
1.3 Restraints for Alpha Thalassemia Market
1.4 Opportunities for Alpha Thalassemia Market
1.5 Trends for Alpha Thalassemia Market
1.6 Macro-economic Factors
1.7 Regulatory Framework
1.8 Opportunity Map Analysis
1.9 Opportunity Orbits
1.10 Market Investment Feasibility Index
1.11 PEST Analysis
1.12 PORTER’S Five Force Analysis
1.13 Go to Market Strategy
1.14 Marketing Strategy
1.15 Technology Roadmap
1.16 Advances in product/services adoption worldwide
1.17 Regional Market Share and BPS Analysis
Chapter 2 Global Alpha Thalassemia Market Competitive Analysis
2.1 Market Competition Scenario Analysis, By Company
2.2 Competitor Landscape
2.3 Major Strategies adopted by key market players (2020-2022)
2.4 Recent Developments/Investments/Announcements
2.5 Company Profiles
2.5.1 Bluebird Bio
2.5.1.1 Company Overview
2.5.1.2 Business Description
2.5.1.3 Product Portfolio
2.5.1.4 Key Financials
2.5.1.5 Company Presence & Business Segment Analysis – 2022
2.5.1.6 Key Developments
2.5.1.7 SWOT Analysis
2.5.2 Acceleron Pharma
2.5.2.1 Company Overview
2.5.2.2 Business Description
2.5.2.3 Product Portfolio
2.5.2.4 Key Financials
2.5.2.5 Company Presence & Business Segment Analysis – 2022
2.5.2.6 Key Developments
2.5.2.7 SWOT Analysis
2.5.3 Novartis AG
2.5.3.1 Company Overview
2.5.3.2 Business Description
2.5.3.3 Product Portfolio
2.5.3.4 Key Financials
2.5.3.5 Company Presence & Business Segment Analysis – 2022
2.5.3.6 Key Developments
2.5.3.7 SWOT Analysis
2.5.4 Sangamo Therapeutics
2.5.4.1 Company Overview
2.5.4.2 Business Description
2.5.4.3 Product Portfolio
2.5.4.4 Key Financials
2.5.4.5 Company Presence & Business Segment Analysis – 2022
2.5.4.6 Key Developments
2.5.4.7 SWOT Analysis
2.5.5 CRISPR Therapeutics
2.5.5.1 Company Overview
2.5.5.2 Business Description
2.5.5.3 Product Portfolio
2.5.5.4 Key Financials
2.5.5.5 Company Presence & Business Segment Analysis – 2022
2.5.5.6 Key Developments
2.5.5.7 SWOT Analysis
2.5.6 Global Blood Therapeutics
2.5.6.1 Company Overview
2.5.6.2 Business Description
2.5.6.3 Product Portfolio
2.5.6.4 Key Financials
2.5.6.5 Company Presence & Business Segment Analysis – 2022
2.5.6.6 Key Developments
2.5.6.7 SWOT Analysis
2.5.7 Celgene Corporation
2.5.7.1 Company Overview
2.5.7.2 Business Description
2.5.7.3 Product Portfolio
2.5.7.4 Key Financials
2.5.7.5 Company Presence & Business Segment Analysis – 2022
2.5.7.6 Key Developments
2.5.7.7 SWOT Analysis
2.5.8 Shire Pharmaceuticals
2.5.8.1 Company Overview
2.5.8.2 Business Description
2.5.8.3 Product Portfolio
2.5.8.4 Key Financials
2.5.8.5 Company Presence & Business Segment Analysis – 2022
2.5.8.6 Key Developments
2.5.8.7 SWOT Analysis
2.5.9 ApoPharma Inc.
2.5.9.1 Company Overview
2.5.9.2 Business Description
2.5.9.3 Product Portfolio
2.5.9.4 Key Financials
2.5.9.5 Company Presence & Business Segment Analysis – 2022
2.5.9.6 Key Developments
2.5.9.7 SWOT Analysis
2.5.10 La Jolla Pharmaceutical Company
2.5.10.1 Company Overview
2.5.10.2 Business Description
2.5.10.3 Product Portfolio
2.5.10.4 Key Financials
2.5.10.5 Company Presence & Business Segment Analysis – 2022
2.5.10.6 Key Developments
2.5.10.7 SWOT Analysis
Chapter 3 Global Alpha Thalassemia Market Overview
3.1 Global Alpha Thalassemia Market Outlook (2017-2032)
3.1.1 Global Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
3.1.2 Global Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
3.2 Global Alpha Thalassemia Market by Region
3.2.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
3.2.2 Global Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
3.3 Global Alpha Thalassemia Market by Type
3.3.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
3.3.2 Global Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
3.3.3 Global Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
3.4 Global Alpha Thalassemia Market by Treatment
3.4.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
3.4.2 Global Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
3.5 Global Alpha Thalassemia Market Value (US$ Mn) by Region
3.5.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
3.5.2 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
3.6 Global Alpha Thalassemia Market Value (US$ Mn) by Type
3.6.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
3.6.2 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
3.7 Global Alpha Thalassemia Market Value (US$ Mn) by Treatment
3.7.1 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
3.7.2 Global Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
3.8 Global Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
3.8.1 Global Alpha Thalassemia Market Y-o-Y Growth Rate by Region
3.8.2 Global Alpha Thalassemia Market Y-o-Y Growth Rate by Type
3.8.3 Global Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
3.9 Global Alpha Thalassemia Market Share Comparison 2017–2032
3.9.1 Global Alpha Thalassemia Market Share by Region
3.9.2 Global Alpha Thalassemia Market Share by Type
3.9.3 Global Alpha Thalassemia Market Share by Treatment
Chapter 4 North America Alpha Thalassemia Market Overview
4.1 North America Market Snapshot
4.1.1 Regional Overview
4.1.1.1 US
4.1.1.2 Canada
4.1.1.3 Mexico
4.2 North America Alpha Thalassemia Market Outlook (2017-2032)
4.2.1 North America Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
4.2.2 North America Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
4.3 North America Alpha Thalassemia Market by Region
4.3.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
4.3.2 North America Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
4.4 North America Alpha Thalassemia Market by Type
4.4.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
4.4.2 North America Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
4.4.3 North America Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
4.5 North America Alpha Thalassemia Market by Treatment
4.5.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
4.5.2 North America Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
4.6 North America Alpha Thalassemia Market Value (US$ Mn) by Region
4.6.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
4.6.2 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
4.7 North America Alpha Thalassemia Market Value (US$ Mn) by Type
4.7.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
4.7.2 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
4.8 North America Alpha Thalassemia Market Value (US$ Mn) by Treatment
4.8.1 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
4.8.2 North America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
4.9 North America Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
4.9.1 North America Alpha Thalassemia Market Y-o-Y Growth Rate by Region
4.9.2 North America Alpha Thalassemia Market Y-o-Y Growth Rate by Type
4.9.3 North America Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
4.1 North America Alpha Thalassemia Market Share Comparison 2017–2032
4.10.1 North America Alpha Thalassemia Market Share by Region
4.10.2 North America Alpha Thalassemia Market Share by Type
4.10.3 North America Alpha Thalassemia Market Share by Treatment
Chapter 5 Europe Alpha Thalassemia Market Overview
5.1 Europe Market Snapshot
5.1.1 Regional Overview
5.1.1.1 Germany
5.1.1.2 United Kingdom
5.1.1.3 France
5.1.1.4 Italy
5.1.1.5 Spain
5.1.1.6 Russia
5.1.1.7 Rest of Europe
5.2 Europe Alpha Thalassemia Market Outlook (2017-2032)
5.2.1 Europe Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
5.2.2 Europe Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
5.3 Europe Alpha Thalassemia Market by Region
5.3.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
5.3.2 Europe Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
5.4 Europe Alpha Thalassemia Market by Type
5.4.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
5.4.2 Europe Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
5.4.3 Europe Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
5.5 Europe Alpha Thalassemia Market by Treatment
5.5.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
5.5.2 Europe Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
5.6 Europe Alpha Thalassemia Market Value (US$ Mn) by Region
5.6.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
5.6.2 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
5.7 Europe Alpha Thalassemia Market Value (US$ Mn) by Type
5.7.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
5.7.2 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
5.8 Europe Alpha Thalassemia Market Value (US$ Mn) by Treatment
5.8.1 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
5.8.2 Europe Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
5.9 Europe Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
5.9.1 Europe Alpha Thalassemia Market Y-o-Y Growth Rate by Region
5.9.2 Europe Alpha Thalassemia Market Y-o-Y Growth Rate by Type
5.9.3 Europe Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
5.1 Europe Alpha Thalassemia Market Share Comparison 2017–2032
5.10.1 Europe Alpha Thalassemia Market Share by Region
5.10.2 Europe Alpha Thalassemia Market Share by Type
5.10.3 Europe Alpha Thalassemia Market Share by Treatment
Chapter 6 Asia Pacific Alpha Thalassemia Market Overview
6.1 Asia Pacific Market Snapshot
6.1.1 Regional Overview
6.1.1.1 China
6.1.1.2 India
6.1.1.3 Japan
6.1.1.4 Australia
6.1.1.5 Rest of Asia Pacific
6.2 Asia Pacific Alpha Thalassemia Market Outlook (2017-2032)
6.2.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
6.2.2 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
6.3 Asia Pacific Alpha Thalassemia Market by Region
6.3.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
6.3.2 Asia Pacific Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
6.4 Asia Pacific Alpha Thalassemia Market by Type
6.4.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
6.4.2 Asia Pacific Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
6.4.3 Asia Pacific Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
6.5 Asia Pacific Alpha Thalassemia Market by Treatment
6.5.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
6.5.2 Asia Pacific Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
6.6 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) by Region
6.6.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
6.6.2 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
6.7 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) by Type
6.7.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
6.7.2 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
6.8 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) by Treatment
6.8.1 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
6.8.2 Asia Pacific Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
6.9 Asia Pacific Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
6.9.1 Asia Pacific Alpha Thalassemia Market Y-o-Y Growth Rate by Region
6.9.2 Asia Pacific Alpha Thalassemia Market Y-o-Y Growth Rate by Type
6.9.3 Asia Pacific Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
6.1 Asia Pacific Alpha Thalassemia Market Share Comparison 2017–2032
6.10.1 Asia Pacific Alpha Thalassemia Market Share by Region
6.10.2 Asia Pacific Alpha Thalassemia Market Share by Type
6.10.3 Asia Pacific Alpha Thalassemia Market Share by Treatment
Chapter 7 South America Alpha Thalassemia Market Overview
7.1 South America Market Snapshot
7.1.1 Regional Overview
7.1.1.1 Brazil
7.1.1.2 Argentina
7.1.1.3 Rest of South America
7.2 South America Alpha Thalassemia Market Outlook (2017-2032)
7.2.1 South America Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
7.2.2 South America Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
7.3 South America Alpha Thalassemia Market by Region
7.3.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
7.3.2 South America Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
7.4 South America Alpha Thalassemia Market by Type
7.4.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
7.4.2 South America Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
7.4.3 South America Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
7.5 South America Alpha Thalassemia Market by Treatment
7.5.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
7.5.2 South America Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
7.6 South America Alpha Thalassemia Market Value (US$ Mn) by Region
7.6.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
7.6.2 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
7.7 South America Alpha Thalassemia Market Value (US$ Mn) by Type
7.7.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
7.7.2 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
7.8 South America Alpha Thalassemia Market Value (US$ Mn) by Treatment
7.8.1 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
7.8.2 South America Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
7.9 South America Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
7.9.1 South America Alpha Thalassemia Market Y-o-Y Growth Rate by Region
7.9.2 South America Alpha Thalassemia Market Y-o-Y Growth Rate by Type
7.9.3 South America Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
7.1 South America Alpha Thalassemia Market Share Comparison 2017–2032
7.10.1 South America Alpha Thalassemia Market Share by Region
7.10.2 South America Alpha Thalassemia Market Share by Type
7.10.3 South America Alpha Thalassemia Market Share by Treatment
Chapter 8 Middle East and Africa Alpha Thalassemia Market Overview
8.1 Middle East and Africa Market Snapshot
8.1.1 Regional Overview
8.1.1.1 GCC
8.1.1.2 South Africa
8.1.1.3 Israel
8.1.1.4 Rest of Middle East and Africa
8.2 Middle East and Africa Alpha Thalassemia Market Outlook (2017-2032)
8.2.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) (2017-2023)
8.2.2 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) (2024-2032)
8.3 Middle East and Africa Alpha Thalassemia Market by Region
8.3.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2032)
8.3.2 Middle East and Africa Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
8.4 Middle East and Africa Alpha Thalassemia Market by Type
8.4.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2032)
8.4.2 Middle East and Africa Alpha Thalassemia Market Attractiveness Analysis by Type, 2023–2032
8.4.3 Middle East and Africa Alpha Thalassemia Market Attractiveness Analysis by Region, 2023–2032
8.5 Middle East and Africa Alpha Thalassemia Market by Treatment
8.5.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2032)
8.5.2 Middle East and Africa Alpha Thalassemia Market Attractiveness Analysis by Treatment, 2023–2032
8.6 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) by Region
8.6.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2017-2023)
8.6.2 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Region (2024-2032)
8.7 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) by Type
8.7.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2017-2023)
8.7.2 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Type (2024-2032)
8.8 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) by Treatment
8.8.1 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2017-2023)
8.8.2 Middle East and Africa Alpha Thalassemia Market Value (US$ Mn) Comparison by Treatment (2024-2032)
8.9 Middle East and Africa Alpha Thalassemia Market Y-o-Y Growth Rate Comparison 2018–2032
8.9.1 Middle East and Africa Alpha Thalassemia Market Y-o-Y Growth Rate by Region
8.9.2 Middle East and Africa Alpha Thalassemia Market Y-o-Y Growth Rate by Type
8.9.3 Middle East and Africa Alpha Thalassemia Market Y-o-Y Growth Rate by Treatment
8.1 Middle East and Africa Alpha Thalassemia Market Share Comparison 2017–2032
8.10.1 Middle East and Africa Alpha Thalassemia Market Share by Region
8.10.2 Middle East and Africa Alpha Thalassemia Market Share by Type
8.10.3 Middle East and Africa Alpha Thalassemia Market Share by Treatment
Chapter 9 Methodology and Data Source
9.1 Research Approach/ Methodology
9.2 Market Size Estimation
9.3 Market Breakdown and Data Triangulation
9.4 Data Source
9.4.1 Secondary Sources
9.4.2 Primary Sources

License

Single User, Corporate User, Data Pack / Excel

Single User
$3,499
Corporate User
$6,999
Data Pack / Excel
$999
Compare Added Add to Wishlist Browse Wishlist
Compare Products
No products were added to compare list
Return to Shop
Food Color Ingredients Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Electrophysiology Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Prefilled Syringes Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Catheters Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Renal Denervation Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Implantable Medical Devices Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Medical Implant Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Medical Batteries Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Gynecological Devices Market 2025, Global Dynamics, Trends & Forecast
0 customer review
Chilled Food Packaging Market 2024, Global Dynamics, Trends & Forecast
0 customer review
Chilled Food Packaging Market 2024, Global Dynamics, Trends & Forecast